These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 33537001)

  • 21. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
    Pea A; Hruban RH; Wood LD
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.
    Wong HL; Yang KC; Shen Y; Zhao EY; Loree JM; Kennecke HF; Kalloger SE; Karasinska JM; Lim HJ; Mungall AJ; Feng X; Davies JM; Schrader K; Zhou C; Karsan A; Jones SJM; Laskin J; Marra MA; Schaeffer DF; Gorski SM; Renouf DJ
    Cold Spring Harb Mol Case Stud; 2018 Feb; 4(1):. PubMed ID: 29092957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.
    Martin DR; LaBauve E; Pomo JM; Chiu VK; Hanson JA; Gullapalli RR
    Pancreas; 2018 Apr; 47(4):502-510. PubMed ID: 29521944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated clinicopathological features and gene microarray analysis of pancreatic neuroendocrine tumors.
    Zhou H; Chen Q; Tan W; Qiu Z; Li S; Song Y; Gao S
    Gene; 2017 Aug; 625():72-77. PubMed ID: 28479381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the management of unresectable or metastatic pancreatic neuroendocrine tumors: chemotherapy, targeted therapy, hormonal treatment, and future directions.
    Bilici A
    Asian Pac J Cancer Prev; 2015; 16(6):2151-9. PubMed ID: 25824731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Animal models and cell lines of pancreatic neuroendocrine tumors.
    Babu V; Paul N; Yu R
    Pancreas; 2013 Aug; 42(6):912-23. PubMed ID: 23851429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
    Luchini C; Lawlor RT; Bersani S; Vicentini C; Paolino G; Mattiolo P; Pea A; Cingarlini S; Milella M; Scarpa A
    Curr Oncol Rep; 2021 Jul; 23(9):106. PubMed ID: 34269919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors.
    Komori Y; Yada K; Ohta M; Uchida H; Iwashita Y; Fukuzawa K; Kashima K; Yokoyama S; Inomata M; Kitano S
    J Hepatobiliary Pancreat Sci; 2014 Apr; 21(4):288-95. PubMed ID: 24002888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endoplasmic Reticulum Stress in Pancreatic Neuroendocrine Tumors is Linked to Clinicopathological Parameters and Possible Epigenetic Regulations.
    Klieser E; Illig R; Státtner S; Primavesi F; Jáger T; Swierczynski S; Kiesslich T; Kemmerling R; Bollmann C; Di Fazio P; Neureiter D
    Anticancer Res; 2015 Nov; 35(11):6127-36. PubMed ID: 26504039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
    Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
    J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
    Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pancreatic neuroendocrine tumors: pathologic and molecular characteristics.
    Shi C; Klimstra DS
    Semin Diagn Pathol; 2014 Nov; 31(6):498-511. PubMed ID: 25441311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. α-Internexin: a novel biomarker for pancreatic neuroendocrine tumor aggressiveness.
    Liu B; Tang LH; Liu Z; Mei M; Yu R; Dhall D; Qiao XW; Zhang TP; Zhao YP; Liu TH; Xiao Y; Chen J; Xiang HD; Wu HY; Lu CM; Lv B; Zhou YR; Zhang Y; Deng D; Chen YJ
    J Clin Endocrinol Metab; 2014 May; 99(5):E786-95. PubMed ID: 24483152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.
    Saller J; Seydafkan S; Shahid M; Gadara M; Cives M; Eschrich SA; Boulware D; Strosberg JR; Aejaz N; Coppola D
    Cancer Genomics Proteomics; 2019; 16(5):309-318. PubMed ID: 31467225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of everolimus in pancreatic neuroendocrine tumors.
    Goldstein R; Meyer T
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors.
    Gloesenkamp CR; Nitzsche B; Ocker M; Di Fazio P; Quint K; Hoffmann B; Scherübl H; Höpfner M
    Int J Oncol; 2012 Mar; 40(3):876-88. PubMed ID: 22075556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.
    Strosberg JR; Fisher GA; Benson AB; Anthony LB; Arslan B; Gibbs JF; Greeno E; Iyer RV; Kim MK; Maples WJ; Philip PA; Wolin EM; Cherepanov D; Broder MS
    World J Gastroenterol; 2015 Feb; 21(8):2450-9. PubMed ID: 25741154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Molecular and Clinical Landscape of Pancreatic Neuroendocrine Tumors.
    Batukbhai BDO; De Jesus-Acosta A
    Pancreas; 2019 Jan; 48(1):9-21. PubMed ID: 30531241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of multiomics sequencing and advances in the molecular mechanisms of pancreatic neuroendocrine neoplasms.
    Jiang R; Hong X; Zhao Y; Wu W
    Cancer Lett; 2021 Feb; 499():39-48. PubMed ID: 33246093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.